83 FR 4499 - National Heart, Lung, and Blood Institute; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 83, Issue 21 (January 31, 2018)

Page Range		4499-4499
FR Document		2018-01930

Federal Register, Volume 83 Issue 21 (Wednesday, January 31, 2018)

[Federal Register Volume 83, Number 21 (Wednesday, January 31, 2018)]
[Notices]
[Page 4499]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-01930]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Heart, Lung, and Blood Institute; Notice of Closed 
Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of a meeting of the NHLBI Mentored 
Transition to Independence Review Committee.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Heart, Lung, and Blood Initial Review Group; 
NHLBI Mentored Transition to Independence Review Committee.
    Date: March 8-9, 2018.
    Time: 8:00 a.m. to 1:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: The William F. Bolger Center, 9600 Newbridge Drive, 
Potomac, MD 20854.
    Contact Person: Giuseppe Pintucci, Ph.D., Scientific Review 
Officer, Office of Scientific Review/DERA, National Heart, Lung, and 
Blood Institute, 6701 Rockledge Drive, Room 7192, Bethesda, MD 
20892, 301-435-0287, Pintuccig@nhlbi.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, 
National Center for Sleep Disorders Research; 93.837, Heart and 
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, 
Blood Diseases and Resources Research, National Institutes of 
Health, HHS)

    Dated: January 26, 2018.
Michelle Trout,
 Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-01930 Filed 1-30-18; 8:45 am]
BILLING CODE 4140-01-P

Federal Register / Vol. 83, No. 21 / Wednesday, January 31, 2018 / Notices 4499

Government and are available for Development Stage: DEPARTMENT OF HEALTH AND
licensing in the U.S. • In vitro data available. HUMAN SERVICES
FOR FURTHER INFORMATION CONTACT:
Inventors: Paul Winfield, Norman National Institutes of Health
Licensing information and copies of the
Watts, Alasdair Steven (all of NIAMS).
patent applications listed below may be
Intellectual Property: HHS Reference National Heart, Lung, and Blood
obtained by emailing the indicated
No. E–192–2017/0–US–01. Institute; Notice of Closed Meeting
licensing contact at the National Heart,
Lung, and Blood, Office of Technology • U.S. Provisional Patent Application Pursuant to section 10(d) of the
Transfer and Development Office of 62/534,603 filed July 19, 2017. Federal Advisory Committee Act, as
Technology Transfer, 31 Center Drive amended, notice is hereby given of a
Licensing Contact: Michael
Room 4A29, MSC2479, Bethesda, MD meeting of the NHLBI Mentored
20892–2479; telephone: 301–402–5579. Shmilovich, Esq, CLP; 301–435–5019;
Transition to Independence Review
A signed Confidential Disclosure shmilovm@nih.gov.
Committee.
Agreement may be required to receive Collaborative Research Opportunity: The meeting will be closed to the
copies of the patent applications. The National Institute of Environmental public in accordance with the
SUPPLEMENTARY INFORMATION: This Health Sciences seeks statements of provisions set forth in sections
notice is in accordance with 35 U.S.C. capability or interest from parties 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
209 and 37 CFR part 404 to achieve interested in collaborative research to as amended. The grant applications and
commercialization of results of further develop and evaluate, please the discussions could disclose
federally-funded research and contact Cecilia Pazman, Ph.D., confidential trade secrets or commercial
development. Foreign patent Technology Development Specialist, property such as patentable material,
applications are filed on selected Office of Technology Transfer, National and personal information concerning
inventions to extend market coverage Heart, Lung, and Blood Institute, Phone: individuals associated with the grant
for companies and may also be available (301) 594–4273; pazmance@ applications, the disclosure of which
for licensing. A description of the nhlbi.nih.gov. would constitute a clearly unwarranted
technology follows. invasion of personal privacy.
Dated: January 25, 2018.
Chimeric Antibodies Against Hepatitis Name of Committee: Heart, Lung, and
Michael Shmilovich, Blood Initial Review Group; NHLBI
B e-Antigen Senior Licensing and Patenting Manager, Mentored Transition to Independence
Description of Technology: The National Heart, Lung, and Blood Institute, Review Committee.
invention relates to recombinant Office of Technology Transfer and Date: March 8–9, 2018.
chimeric rabbit/human monoclonal Development. Time: 8:00 a.m. to 1:00 p.m.
antibody fragments (Fabs) against [FR Doc. 2018–01928 Filed 1–30–18; 8:45 am] Agenda: To review and evaluate grant
hepatitis B Virus e-antigen (HBeAg), applications.
BILLING CODE 4140–01–P
Place: The William F. Bolger Center, 9600
notably Fab me6. Viral hepatitis is the Newbridge Drive, Potomac, MD 20854.
seventh leading cause of death Contact Person: Giuseppe Pintucci, Ph.D.,
worldwide. Hepatitis B core antigen DEPARTMENT OF HEALTH AND Scientific Review Officer, Office of Scientific
(HBcAg) forms an icosahedral structure HUMAN SERVICES Review/DERA, National Heart, Lung, and
containing the viral genome. Both the Blood Institute, 6701 Rockledge Drive, Room
HBcAg and the HBeAg of interest here National Institutes of Health 7192, Bethesda, MD 20892, 301–435–0287,
are expressed by two different start Pintuccig@nhlbi.nih.gov.
codons of the viral C gene. Unlike the Center for Scientific Review; Amended (Catalogue of Federal Domestic Assistance
related HBcAg which activates type 1 T Notice of Meeting Program Nos. 93.233, National Center for
helper (Th1) cells leading to immune Sleep Disorders Research; 93.837, Heart and
attack, the HBeAg activates Th2 cells Notice is hereby given of a change in Vascular Diseases Research; 93.838, Lung
the meeting of the Skeletal Biology Diseases Research; 93.839, Blood Diseases
which promote immune tolerance. The and Resources Research, National Institutes
long-term persistence of HBeAg is Development and Disease Study of Health, HHS)
associated with the development of Section, February 8, 2018, 8:00 a.m. to
hepatocellular carcinoma. Conversely, February 9, 2018, 3:00 p.m., Westin Dated: January 26, 2018.
HBeAg seroconversion (from HBeAg Baltimore Washington Airport, 1100 Michelle Trout,
carrier to anti-HBeAg carrier) is a Old Elkridge Landing Road, Linthicum Program Analyst, Office of Federal Advisory
marker for successful therapy of Heights, MD, 21090 which was Committee Policy.
chronically infected patients. The published in the Federal Register on [FR Doc. 2018–01930 Filed 1–30–18; 8:45 am]
presently phage display engineered January 5, 2018, 83 FR PG 683. The BILLING CODE 4140–01–P
antibody Fab me6 shows higher meeting will be held on February 7,
sensitivity and selectivity against 2018 at 3:00 p.m. and end February 8,
HBeAg compared to three commercial DEPARTMENT OF HEALTH AND
2018 at 9:00 p.m. The meeting location
diagnostics kits tested; additionally, it HUMAN SERVICES
remains the same. The meeting is closed
also inhibits capsid assembly which is to the public.
essential for viral replication; National Institutes of Health
Dated: January 25, 2018.
sradovich on DSK3GMQ082PROD with NOTICES

furthermore, it can also be fully National Institute on Aging; Amended
humanized and has potential for anti- Melanie J. Pantoja,
Notice of Meeting
hepatitis B virus therapeutic Program Analyst, Office of Federal Advisory
interventions. Committee Policy. Notice is hereby given of a change in
Potential Commercial Applications: [FR Doc. 2018–01821 Filed 1–30–18; 8:45 am] the meeting of the National Advisory
• Hepatitis B therapy. BILLING CODE 4140–01–P
Council on Aging, January 23, 2018,
• Hepatocellular carcinoma 3:00 p.m. to January 24, 2018, 2:00 p.m.,
prophylaxis. National Institutes of Health, Building

VerDate Sep<11>2014 17:36 Jan 30, 2018 Jkt 244001 PO 00000 Frm 00037 Fmt 4703 Sfmt 4703 E:\FR\FM\31JAN1.SGM 31JAN1

Document Created: 2018-01-31 00:59:06
Document Modified: 2018-01-31 00:59:06

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		March 8-9, 2018.
FR Citation		83 FR 4499

83 FR 4499 - National Heart, Lung, and Blood Institute; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 83, Issue 21 (January 31, 2018)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health